Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Purpose/Background: Schizophrenia is a chronic, debilitating mental illness that incurs a large economic burden. Decreasing hospital readmissions is a priority in health care to improve patient quality of life and decrease health care costs. Determining ways to prevent readmissions such as improving access to long-acting injectable (LAI) antipsychotics is important to assess. Methods/Procedures: A single-center retrospective review was conducted comparing readmission rates of patients diagnosed with schizophrenia or schizoaffective disorder discharged on LAI or oral antipsychotics between August 1, 2019, and June 30, 2022. The primary outcome was the 30-day psychiatric readmission rate. Secondary outcomes included chlorpromazine equivalent doses and use of anticholinergic medications. Findings/Results: The 30-day readmission rate was 1.9% for the LAI antipsychotic group and 8.3% for the oral antipsychotic group (P = 0.03; 95% confidence interval, 1.05–20.02). The average chlorpromazine equivalent antipsychotic dose of patients discharged on LAI versus oral antipsychotic medications was 477.3 and 278.6 mg/d, respectively (P < 0.001). In addition, the prevalence of medications used to treat extrapyramidal symptom was 22.3% (n = 23) for the LAI antipsychotic group and 30.8% (n = 74) for the oral antipsychotic group (P = 0.12). Sixty-four percent of LAI antipsychotics utilized were obtained from pharmaceutical company hospital inpatient free trial programs. Implications/Conclusions: Long-acting injectable antipsychotics showed a statistically significant reduction in 30-day rehospitalizations as compared with oral antipsychotics and hospital inpatient free trial programs aided in LAI antipsychotic acquisition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Correll, C. U., & Schooler, N. R. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s225643 · Cited by 911
Reducing Hospital Readmission Rates: Current Strategies and Future Directions
Kripalani, S., Theobald, C. N., Anctil, B., & Vasilevskis, E. E. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-022613-090415 · Cited by 576
The Economic Burden of Schizophrenia in the United States in 2013
Cloutier, M., Sanon Aigbogun, M., Guerin, A., Nitulescu, R., Ramanakumar, A. V., Kamat, S. A., DeLucia, M., Duffy, R., Legacy, S. N., Henderson, C., et al. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10278 · Cited by 477
Hospital Strategies Associated With 30-Day Readmission Rates for Patients With Heart Failure
Bradley, E. H., Curry, L., Horwitz, L. I., Sipsma, H., Wang, Y., Walsh, M. N., Goldmann, D., White, N., Piña, I. L., & Krumholz, H. M. (2013) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000101 · Cited by 346
The Economic Burden of Schizophrenia in the United States
Kadakia, A., Catillon, M., Fan, Q., Williams, G. R., Marden, J. R., Anderson, A., Kirson, N., & Dembek, C. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22m14458 · Cited by 204
Uitvlugt, E. B., Janssen, M. J. A., Siegert, C. E. H., Kneepkens, E. L., van den Bemt, B. J. F., van den Bemt, P. M. L. A., & Karapinar‐Çarkit, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.567424 · Cited by 98
Kim, H. O., Seo, G. H., & Lee, B. C. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-019-0254-2 · Cited by 79
Risk factors for readmission in schizophrenia patients following involuntary admission
Hung, Y., Chan, H., & Pan, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186768 · Cited by 65
Lin, D., Joshi, K., Keenan, A., Shepherd, J., Bailey, H. M. L., Berry, M., Wright, J., Meakin, S., Benson, C. J., & Kim, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.695672 · Cited by 55
Research works printed but not linked: 1
- 2022, What are dose conversions from oral to injectable for the long-acting injectable (LAI) antipsychotic medications available in the U.S., SMI Advisor
Cited by
Sun, C. N., Temelie, A., Goulding, H., Clark, C., Yabs, M., & Fabian, T. J. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0024 · Cited by 8
“LAIA use in this patient population has been associated with improved outcomes such lower relapse rates, longer time to relapse, and fewer hospital days when compared to adult patients treated with oral antipsychotics (Huang et al., 2021; Lytle et al., 2017; Park et al, 2018; Thaman et al., 2024).”
Sun, C. N., Temelie, A., Goulding, H., Clark, C., Yabs, M., & Fabian, T. J. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0072 · Cited by 3
“…schizophrenia, schizoaffective disorder, and bipolar disorder with several studies showcasing increased adherence rates, reduced hospitalizations, and an overall reduction in healthcare costs with LAIA utilization (Correll et al., 2017; Park et al., 2018; Huang et al., 2021; Thaman et al., 2024).”
Tunagur, E. M. K., & Tunagür, M. T. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07801-y · Cited by 3
“Long-acting injectable (LAI) antipsychotics have emerged as a crucial advancement in the treatment of chronic psychiatric disorders and offer a viable alternative to oral antipsychotic medications [11, 31].”
Jeong, H. W., Kim, Y. S., Kim, E., Bhang, S., Choi, J.-W., Jeong, J. H., Kang, H., & Lee, K. Y. (2026) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000621 · Cited by 1
Metadata
- Authors
- Thaman, P., Kulig, C. E., & Greer, D.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- Greer, Daniel
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2024-01-16
- Volume
- 44
- Issue
- 2
- Pages
- 96-99
- ISSN
- 0271-0749 (ISSN-L)
- 1533-712X
- OpenAlex
- W4390903411
- Cited by
- 4
- References
- 17
- Citations by year
- 2026: 2 · 2024: 2
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Social Sciences › Psychology › Clinical Psychology › Historical Psychiatry and Medical Practices
- Keywords
- long-acting injectable antipsychotics, oral antipsychotics, schizophrenia, schizoaffective disorder, psychiatric rehospitalization, hospital readmission, chlorpromazine equivalents, anticholinergic agents, extrapyramidal symptoms, access to medicines
- MeSH terms
- Administration, Oral, Chlorpromazine, Delayed-Action Preparations, Humans, Injections, Patient Readmission, Quality of Life, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations. https://app.cochat.ai/papers/10.1097/jcp.0000000000001810
- The paper
- Thaman, P., Kulig, C. E., & Greer, D. (2024). Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000001810
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.